author-photo

Olivier Molinier

University of Montpellier

124

Papers

3257

Citations

Citation Trend

Filter By

Papers (85) Sort By

Journal Conference Others

ALK-2016-CPHG: étude observationnelle prospective multicentrique en vie réelle de cancers bronchiques réarrangés ALK ou ROS1 traités par crizotinib

2021 Revue des Maladies Respiratoires Actualités
Show All
- Source
- Cite
- Save
Citations (0)
First-line Afatinib plus Cetuximab for EGFR-mutant Non-small-cell Lung Cancer: Results from the Randomized Phase 2 IFCT-1503 ACE-Lung Study.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (32)
Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: KEYNOTE-598.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non-Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 Mutation.

2021 Clinical Lung Cancer
Show All
- Source
- Cite
- Save
Citations (0)
PS01.09 Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: results of the IFCT-GFPC-1101 multicenter randomized phase III trial

2021 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Real World Data of Efficacy and Safety of Erlotinib as First-Line TKI treatment in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer: Results from the EGFR-2013-CPHG Study

2020
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma

2020 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (25)
Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab.

2020 Journal of Clinical Medicine
Show All
- Source
- Cite
- Save
Citations (5)